These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 28487467)

  • 21. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
    Lang GT; Shi JX; Hu X; Zhang CH; Shan L; Song CG; Zhuang ZG; Cao AY; Ling H; Yu KD; Li S; Sun MH; Zhou XY; Huang W; Shao ZM
    Int J Cancer; 2017 Jul; 141(1):129-142. PubMed ID: 28294317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
    Zavitsanos PJ; Wazer DE; Hepel JT; Wang Y; Singh K; Leonard KL
    Am J Clin Oncol; 2018 Dec; 41(12):1252-1256. PubMed ID: 29782359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Somatically Acquired
    Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
    Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
    J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
    Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival outcomes in patients with
    Musacchio L; Boccia S; Marchetti C; Minucci A; Camarda F; Cassani C; Ventriglia J; Salutari V; Ghizzoni V; Giudice E; Perri MT; Carbone MV; Ricci C; Pignata S; Fagotti A; Scambia G; Lorusso D
    Int J Gynecol Cancer; 2023 Jun; 33(6):922-928. PubMed ID: 36759000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer following ovarian cancer in BRCA mutation carriers.
    Gangi A; Cass I; Paik D; Barmparas G; Karlan B; Dang C; Li A; Walsh C; Rimel BJ; Amersi FF
    JAMA Surg; 2014 Dec; 149(12):1306-13. PubMed ID: 25372568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    Lee YJ; Kim HS; Rim JH; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    BMC Cancer; 2020 Mar; 20(1):185. PubMed ID: 32131779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
    Wu X; Wu L; Kong B; Liu J; Yin R; Wen H; Li N; Bu H; Feng Y; Li Q; Lu X; Wei J; Zhu X; Mills J; Ellison G; Gutjahr T; Liu Y
    Int J Gynecol Cancer; 2017 Oct; 27(8):1650-1657. PubMed ID: 28692638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
    Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation.
    Yamashita Y; Ishii Y; Serikawa M; Okamoto W; Tsuboi T; Tatsukawa Y; Nakamura S; Hirano T; Ikemoto J; Oka S
    Clin J Gastroenterol; 2023 Jun; 16(3):470-475. PubMed ID: 36806982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.